Multicenter prospective phase II study of decitabine priming with low-dose idarubicin, cytarabine, and G-CSF in children with refractory or relapsed acute myeloid leukemia
No standard salvage regimen exists for relapsed/refractory (R/R) pediatric AML. In this prospective, multicenter Phase II trial, 101 evaluable patients (.
Authors
- Y H Wang
- R C Ribeiro
- Jixia Luo
- Yeting He
- Ningling Wang (ORCID: https://orcid.org/0000-0001-5185-3968)
- Shaoyan Hu
- Yuan Zhang (ORCID: https://orcid.org/0000-0002-2463-4599)
- Wen Zhang (ORCID: https://orcid.org/0000-0001-5166-0736)
- Liyan Fan
- Xiuli Ju (ORCID: https://orcid.org/0000-0001-6759-1800)
- Ning Liao
- Xueju Xu
- Jun Lu
- Yixin Hu
- Xue Han
- Li Gao
- Hongsheng Wang
- Xiaowen Zhai
- Hailong He
- Cheng Cheng
- Hua Jiang
- Linhai Yang
- Yong Zhuang
- Peifang Xiao
- Hongjun Liu
- Jie Li
Institutions
- University of Science and Technology of China (CN)
- St. Jude Children's Research Hospital (US)
- Soochow University (TW)
- Anhui Medical University (CN)
- Soochow University (CN)
- Guangzhou Women and Children Medical Center (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- Kaifeng City Children's Hospital (CN)
- Second Affiliated Hospital of Anhui Medical University (CN)
- First Affiliated Hospital of Soochow University (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Children's Hospital of Fudan University (CN)
- Qilu Hospital of Shandong University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Haematologica
- Published
- 2026-02-05
- DOI
- https://doi.org/10.3324/haematol.2025.289170
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China